US 11,992,491 B2
Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester
Rudolf Moser, Schaffhausen (CH); Viola Groehn, Dachsen (CH); Ruth Boehni Stamm, Stein Am Rhein (CH); Fritz Blatter, Reinach (CH); and Martin Szelagiewicz, Basel (CH)
Assigned to MERCK PATENT GMBH, Darmstadt (DE)
Appl. No. 17/258,014
Filed by Merck Patent GmbH, Darmstadt (DE)
PCT Filed Jul. 2, 2019, PCT No. PCT/EP2019/067703
§ 371(c)(1), (2) Date Jan. 5, 2021,
PCT Pub. No. WO2020/007841, PCT Pub. Date Jan. 9, 2020.
Claims priority of application No. 18182281 (EP), filed on Jul. 6, 2018.
Prior Publication US 2021/0275533 A1, Sep. 9, 2021
Int. Cl. A61K 31/519 (2006.01); A23L 33/00 (2016.01); A23L 33/10 (2016.01); A61K 31/223 (2006.01)
CPC A61K 31/519 (2013.01) [A23L 33/10 (2016.08); A23L 33/40 (2016.08); A61K 31/223 (2013.01); A23V 2002/00 (2013.01)] 17 Claims
 
1. A crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to L-valine ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol), or a hydrate or solvate thereof.